Skip to content

A study to find out if a new malaria vaccine regimen can protect against malaria in African adults.

Efficacy Study of ChAd63-MVA ME-TRAP prime-boost Vaccination against Plasmodium falciparum infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201202000356208
Enrollment
120
Registered
2012-02-07
Start date
2012-02-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

Sponsors

University of Oxford
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Consenting adult males aged 18 ¿ 50 years in good health. Will remain resident in the study area for the study duration. Able and willing (in the Investigator¿s opinion) to comply with all study requirements Informed Consent

Exclusion criteria

Exclusion criteria: ¿ Any significant medical disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data ¿ Hypersensitivity to HDCRV,the trial vaccines or the antimalarial used. ¿ History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. egg products, kathon, neomycin ¿ History of splenectomy. ¿ Haemoglobin less than 10.0 g/dl ¿ Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels). ¿ Blood transfusion within the month preceding enrolment. ¿ History of vaccination with previous experimental malaria vaccines or other vaccines likely to impact on findings of study (e.g. other MVA or adenovirus vectored vaccines) ¿ Administration of any other vaccine or immunoglobulin within 2 weeks before vaccination. ¿ HIV or Hepatitis B surface antigen seropositivity. ¿ Current participation in another clinical trial or recent participation within 12 weeks of this study. ¿ Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial. ¿ Likelihood of travel away from the study area

Design outcomes

Primary

MeasureTime frame
We will compare active and control vaccination for time to first episode of P.falciparum infection, defined as any blood sample confirmed positive by PCR

Secondary

MeasureTime frame
Vaccine immunogenicity ;Vaccine reactogenicity

Countries

Kenya

Contacts

Public ContactPATRICIA NJUGUNA

Investigator

PNjuguna@kilifi.kemri-wellcome.org(+254) 417 522 535

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026